Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monopar Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer focused on ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers. Its 8-K reports furnish financial results, business updates, Regulation FD clinical presentations, conference materials and executive leadership changes, including ALXN1840 Phase 2 and Phase 3 analyses and MNPR-101 program regulatory updates.
Proxy and material-event filings cover shareholder voting matters, board governance, executive compensation, pay-versus-performance tables, capital-structure disclosures and material agreements. The filing record also provides formal context for reported operating results, financing activity and disclosures tied to investigational drug development and Nasdaq-listed common stock.
Monopar Therapeutics Chief Operating Officer Andrew Cittadine increased his direct equity stake through RSU vesting. On March 31, 2026, 3,514 restricted stock units vested and were settled into an equal number of common shares at a conversion price of $0.00 per share.
To cover withholding taxes on this vesting, 1,571 common shares were withheld by the company at a value of $54.79 per share, rather than sold in the open market. After these transactions, Cittadine directly owned 52,669 shares of Monopar Therapeutics common stock.
Monopar Therapeutics filed Amendment No. 1 to its 2025 annual report to correct the date on the independent auditor’s report from March 27, 2025 to March 27, 2026 and update related officer certifications. The amendment re-presents full 2025 financials, which show a net loss of $13.7 million and year-end cash, cash equivalents and investments totaling about $140.7 million against stockholders’ equity of $137.8 million. Management notes an accumulated deficit of $89.5 million and expects existing cash resources to fund operations at least through December 31, 2027.
Monopar Therapeutics reported fourth-quarter and full-year 2025 results and provided an update on its drug programs. Cash, cash equivalents and short-term investments were $140.4 million as of December 31, 2025, and the company expects this to fund operations through at least December 31, 2027.
Net loss was $5.2 million, or $0.61 per share, for Q4 2025 and $13.7 million, or $1.85 per share, for full-year 2025, both lower than in 2024. R&D expenses fell mainly because 2024 included one-time ALXN1840 in-licensing costs, while G&A expenses rose due to higher personnel and patent expenses.
Monopar plans to submit a New Drug Application for ALXN1840 for Wilson disease in mid-2026 and is advancing its MNPR-101 radiopharmaceutical programs. The leadership team was expanded with a new Chief Commercial and Strategy Officer to support a potential ALXN1840 launch.
Monopar Therapeutics Inc. is a clinical-stage biopharma focused on ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceuticals for advanced cancers. ALXN1840, in-licensed from Alexion in 2024, has Phase 3 data and U.S./EU orphan and FDA Fast Track designations, but regulators may still require more studies before any approval.
The company is running Phase 1 imaging and therapeutic trials in Australia for MNPR-101-Zr and MNPR-101-Lu, plus an FDA-authorized expanded access program in the U.S., and is advancing MNPR-101-Ac preclinically. Cash, cash equivalents and investments were $140.4 million as of December 31, 2025, which management expects to fund operations at least through December 31, 2027, including an anticipated mid-2026 NDA submission for ALXN1840. The 10-K highlights significant future funding needs to commercialize ALXN1840, complete radiopharmaceutical trials, meet up to $94.0 million in Alexion milestones plus 10–20% tiered royalties, and manage intense competition, manufacturing, logistics, and regulatory risks.
Rodriguez Susan reported acquisition or exercise transactions in this Form 4 filing.
Monopar Therapeutics granted Chief Clinical Science Officer Susan Rodriguez stock options covering 48,728 shares on March 2, 2026. The options were reported at a price of $0.0000 per share and are held directly.
According to the vesting terms, 6/48ths of the options vest on September 2, 2026, with the remaining 1/48th vesting each month thereafter. After this grant, Rodriguez was reported as holding 48,728 stock options in total.
Monopar Therapeutics officer Susan Rodriguez filed an initial statement of beneficial ownership on Form 3. She is listed as the company’s CCSO, and the filing does not report any insider stock transactions, focusing instead on establishing her status as a reporting officer.
Monopar Therapeutics filed an 8-K to share that it has appointed seasoned biopharma executive Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. She will lead commercial strategy and infrastructure as the company prepares a planned NDA submission in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease.
Rodriguez brings over 30 years of leadership experience, including senior roles at Avadel Pharmaceuticals, Ardelyx, Tolmar Pharmaceuticals, and Abbott. Her background spans launching rare disease therapies, building commercial organizations, and contributing to Avadel’s acquisition by Alkermes for over $2 billion. The filing also highlights Monopar’s broader pipeline of radiopharmaceutical programs targeting advanced cancers.
RA Capital Management and related entities reported beneficial ownership of 667,632 shares of Monopar Therapeutics common stock, representing 9.99% of the company’s outstanding shares as of December 31, 2025. The RA Capital Healthcare Fund directly holds 667,207 common shares and pre-funded warrants exercisable for up to 1,621,640 additional shares, but a 9.99% beneficial ownership blocker currently allows exercise of only 425 warrant shares. RA Capital, Peter Kolchinsky, and Rajeev Shah are deemed beneficial owners solely for Section 13(d) purposes and certify that the securities are not held to change or influence control of Monopar.
AstraZeneca PLC, through its wholly owned subsidiary Alexion Pharmaceuticals, Inc., has filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership in Monopar Therapeutics Inc. common stock.
The filing states that Alexion directly holds 522,667 shares of Monopar common stock, representing 7.8% of the outstanding shares, based on 6,682,584 shares outstanding as of October 31, 2025, as reported in Monopar’s Form 10-Q. AstraZeneca PLC and Alexion may each be deemed to have sole voting and sole dispositive power over these shares.
The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Monopar, and are not held in connection with any transaction having that purpose or effect.
Tactic Pharma LLC and affiliated holders filed an amended Schedule 13D to report a major change in their Monopar Therapeutics ownership. Tactic Pharma now reports beneficial ownership of 0 shares and 0.0% of Monopar common stock after a liquidating, pro rata distribution of its holdings to its members on January 28, 2026.
Following this distribution, Chandler Robinson reports beneficial ownership of 307,370 shares, or 4.5% of the common stock, including 6,732 restricted stock units and 152,105 stock options that are exercisable or will vest within 60 days. Michael Brown reports 124,629 shares, or 1.8%, including 18,878 stock options. Percentages are based on 6,682,584 shares outstanding as of September 30, 2025. As of January 28, 2026, the reporting group no longer owns more than five percent of Monopar’s common stock, and this amendment is designated as their exit filing.